ABBV vs SNDX: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

ABBV is the larger of the two ($509.92B market cap): the incumbent the market prices for continued execution (17.79x forward earnings, beta 0.19). SNDX is the smaller challenger ($806.65M), still expected to post a loss next year: more room to run, but more to prove. If you believe in growth, SNDX fits: analysts expect its revenue to rise 45% next year, against 9% for ABBV. If you believe in profit, ABBV fits: it is expected to make money next year (17.79x forward earnings), while SNDX is still expected to post a loss.

ABBV vs SNDX: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricABBVSNDXWhat it tells you
Market cap$509.92B$806.65MSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E17.79-11.81Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta0.190.45Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range87% of range3% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.

Before you buy: how ABBV and SNDX affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ABBV and SNDX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ABBV and SNDX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does AbbVie (ABBV) do?

AbbVie is a North Chicago-based research-driven biopharmaceutical company spun off from Abbott Laboratories in 2013. It focuses on discovering and commercializing medicines for immunology, oncology, neuroscience, and aesthetics. Its immunology franchise anchors the business: historically through Humira (adalimumab), and increasingly through Skyrizi (risankizumab) and Rinvoq (upadacitinib), which treat conditions such as plaque psoriasis, Crohn's disease, rheumatoid arthritis, and ulcerative colitis. Oncology contributes through Imbruvica (developed in collaboration with Johnson and Johnson) and Venclexta (in collaboration with Roche), while the 2020 acquisition of Allergan added Botox Therapeutic, Vraylar, and the aesthetics portfolio including Botox Cosmetic and Juvederm. Revenue is generated by selling branded pharmaceuticals at negotiated prices to wholesale distributors, specialty pharmacies, and health systems across more than 175 countries.

Full ABBV guide

What does Syndax Pharmaceuticals (SNDX) do?

Syndax Pharmaceuticals (Nasdaq: SNDX) sells two approved medicines and funds a pipeline behind them. Revuforj (revumenib) is an oral menin inhibitor, approved by the FDA on November 15, 2024 for relapsed or refractory acute leukemia carrying a KMT2A translocation in patients one year and older, then expanded on October 24, 2025 into relapsed or refractory AML with a susceptible NPM1 mutation. Syndax owns it outright in the US, licensed originally from Vitae Pharmaceuticals, now an AbbVie subsidiary, and books its sales as product revenue. Niktimvo (axatilimab-csfr) is a first-in-class antibody against the CSF-1 receptor, approved in August 2024 for chronic graft-versus-host disease after at least two prior lines of systemic therapy in patients weighing 40kg or more. It was in-licensed from UCB Biopharma in 2016 and then partnered with Incyte in September 2021 under a worldwide co-development and co-commercialization agreement. Incyte runs the commercial engine and records the sales; Syndax takes half the net commercial profit. In the third quarter of 2026 Revuforj generated about $61M of net product revenue on roughly 1,700 prescriptions, while Niktimvo generated about $67M of net sales, of which $22.6M reached Syndax as collaboration revenue. The company employed about 298 people at last count.

Full SNDX guide

ABBV vs SNDX: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • ABBV drivers: Skyrizi and Rinvoq replacing Humira faster than expected; Neuroscience becoming a meaningful second growth engine.
  • SNDX drivers: Revuforj moving from KMT2A into the far larger NPM1 population; Niktimvo, where Syndax sees half the profit and none of the sales line.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The single largest structural risk is portfolio concentration: Skyrizi and Rinvoq together account for a rapidly growing share of total revenue, meaning any clinical setback, competitive entry in atopic dermatitis (where Regeneron's Dupixent holds a strong position), or government-mandated price cut under the Inflation Reduction Act could materially impair the growth outlook. For SNDX, revuforj no longer has the menin inhibitor class to itself.

ABBV or SNDX: which should you pick?

If the story you believe is ABBV's (Skyrizi and Rinvoq replacing Humira faster than expected), ABBV is the more direct way to own it; if it is SNDX's (Revuforj moving from KMT2A into the far larger NPM1 population), SNDX is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ABBV and SNDX guides.

ABBV vs SNDX: the full fundamentals

ABBV. The gap between the trailing GAAP P/E (about 50x, inflated by non-cash acquired IPR and D charges on recent deals) and the forward P/E of roughly 17.8x illustrates why analysts and management prefer adjusted metrics: upfront licensing and milestone payments depress reported earnings without reducing cash generation. The trailing multiple has fallen from about 80x in October as a strong Q3 GAAP quarter (about $4.2 billion of net income) replaced weaker ones, while the forward multiple has drifted up with the share price. The 26 covering analysts have a buy consensus and a mean target near $316.

SNDX. Roughly 2.8 times trailing sales is a low multiple for a biotech growing revenue at ~82%, and the reasons are visible in the structure and the pipeline more than the growth rate. Half the franchise arrives as a profit share, the Royalty Pharma instrument skims 13.8% of US Niktimvo sales before anything reaches Syndax, both drugs are approved only in later-line settings, the October 2026 IPF failure removed one route to a much larger market, and the frontline cGVHD readout has moved into 2027. At ~$806M, the market value is only about $255M above the ~$551M of cash and investments, while ~$589M of debt sits ahead of shareholders. Eleven covering analysts carry a mean target near $34, a frontline-expansion number and not a run-rate one.

Headline figures (approximate, November 2026): ABBV shows revenue (ttm) ~$66.0 billion (Q3 2026 ~$17.4B, up ~10% YoY), adjusted eps Q3 2026 $3.82 vs $3.76 estimate; FY2026 consensus ~$13.98; FY2027 consensus ~$16.22, gaap net income (ttm) ~$10.3 billion (GAAP EPS ~$5.82, depressed by acquired IPR and D), margins (ttm) ~74% gross, ~37% operating, ~16% net; SNDX shows revenue (ttm) ~$289.7M for the twelve months to September 30, 2026, against $172.4M in fiscal 2025 and $23.7M in fiscal 2024. The quarterly path was $68.7M in 4Q25, $64.9M in 1Q26 (a sequential dip driven by the January payer and gross-to-net reset, not by demand), $72.8M in 2Q26 and $83.3M in 3Q26, the last of which was up ~82% year over year., product mix (the line that misleads screeners) Of 3Q26's $83.3M, about $61M was Revuforj net product revenue and $22.6M was collaboration revenue representing Syndax's 50% share of Niktimvo net commercial profit, on about $67M of Niktimvo net sales. Combined branded sales of the two medicines were therefore ~$128M in 3Q26 and over $275M across full-year 2025 ($124.8M Revuforj plus $151.6M Niktimvo), well above the reported revenue line., earnings and eps Net loss of $49.4M, or $0.55 per share, in 3Q26, level with 2Q26; trailing twelve-month net loss of ~$209.5M, or ~$2.37 per share. Full-year 2025 net loss was $285.4M and 2024 was $318.8M. There is no P/E, and there has never been an annual profit; consensus has the loss narrowing to ~$0.65 a share in 2027., eps vs estimates and next report 3Q26 loss per share of $0.55 against a ~$0.48 consensus, after 2Q26's $0.55 against ~$0.44 (1Q26: $0.48 loss vs ~$0.59 expected). Fourth-quarter consensus is a ~$0.44 loss on ~$95.8M of revenue; full-year 2026 consensus revenue is ~$316M and 2027 is ~$458M..

The bottom line: ABBV vs SNDX

ABBV and SNDX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined ABBV and SNDX exposure against your real portfolio. It is not an investment adviser.

Wondering how ABBV or SNDX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about AbbVie

Ask Walnut's AI anything about ABBV and see how it fits what you own.

FAQ

What is the difference between ABBV and SNDX?

+

AbbVie is a North Chicago-based research-driven biopharmaceutical company spun off from Abbott Laboratories in 2013. Syndax Pharmaceuticals (Nasdaq: SNDX) sells two approved medicines and funds a pipeline behind them. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is ABBV or SNDX the better stock?

+

Neither is universally better. ABBV is the larger incumbent; SNDX is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, ABBV or SNDX?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both ABBV and SNDX?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of ABBV vs SNDX?

+

ABBV: The single largest structural risk is portfolio concentration: Skyrizi and Rinvoq together account for a rapidly growing share of total revenue, meaning any clinical setback, competitive entry in atopic dermatitis (where Regeneron's Dupixent holds a strong position), or government-mandated price cut under the Inflation Reduction Act could materially impair the growth outlook. AbbVie also carries a heavy debt load, about $81.3 billion as of September 2026 against about $10.8 billion of cash, a legacy of the Allergan acquisition, constraining financial flexibility if credit markets tighten or a major pipeline bet fails. GAAP earnings are depressed by acquired research charges, so the dividend exceeds trailing GAAP net income (a payout ratio near 117% of trailing GAAP EPS of about $5.82), and it is covered by cash flow rather than reported profit. Integrating acquisitions such as Apogee Therapeutics introduces execution risk, the aesthetics segment (Botox Cosmetic, Juvederm) has shown sensitivity to consumer spending cycles, and after a 26% gain in 2026 the shares trade near their highs, though the mean analyst target has risen to about $316. SNDX: Revuforj no longer has the menin inhibitor class to itself. Kura Oncology and Kyowa Kirin won FDA approval for ziftomenib (Komzifti) in November 2025 in relapsed or refractory NPM1-mutated AML, the same population Syndax entered three weeks earlier, and began selling on November 21, 2025. Komzifti is dosed once daily. Both labels carry boxed warnings, including differentiation syndrome and QTc prolongation, so the competition is likely to be fought on dosing convenience, payer access and combination data rather than on a clean safety separation. Kura's partner paid $330M upfront with up to $1.1B in milestones, which funds a serious commercial effort against a Syndax field force that is already carrying two products. Johnson & Johnson and Sumitomo also have menin inhibitors in development. The balance sheet is the second issue. Total stockholders' equity was $15.1M at June 30, 2026 against $688.6M of liabilities, and the accumulated deficit stands at about $1.6B; trailing net losses of ~$209M have eroded that thin cushion further since. The financing is unusual in shape: a $350M upfront from Royalty Pharma in November 2024 that sells 13.8% of US Niktimvo net sales with aggregate payments capped at $822.5M, accounted for as debt, plus $250M of 2.25% convertible senior notes due June 2031 issued in June 2026 at a conversion price near $24.76. Royalty interest expense alone was $12.1M in the second quarter and $24.0M for the half, and it grows as Niktimvo grows. If Niktimvo performs, Syndax pays back up to 2.35 times what it received. The converts add about 10.1M potential shares against 89.4M outstanding. Beyond that, revenue depends on two products in narrow later-line indications, both under UCB and AbbVie-related royalty obligations, with the frontline expansions still unproven. The first quarter of 2026 already showed how sensitive the line is to the January payer reset, falling to $64.9M from $68.7M in the fourth quarter of 2025 despite underlying demand growth. Pipeline risk has already shown up once. The MAXPIRe Phase 2 trial in idiopathic pulmonary fibrosis (145 patients, 26 weeks, axatilimab 0.3 mg/kg every two weeks against placebo) missed its primary endpoint on October 12, 2026, though safety was comparable to placebo. Syndax said the result does not affect trials in other indications, and BofA cut its target to $23 from $26 while keeping a Buy rating. The second readout that mattered, axatilimab plus ruxolitinib in frontline cGVHD, then slipped to the first quarter of 2027, and the company is also going through a chief financial officer transition. The third-quarter loss of $0.55 a share missed the ~$0.48 consensus, the second miss in a row, and the shares fell from ~$13.11 on October 16 to ~$8.95 on November 20, 2026, close to the 52-week low of ~$8.41. UBS cut its target to $31 from $33 on November 20 while keeping a Buy rating.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ABBV or SNDX; figures are approximate and dated (as of November 2026). Verify current data before investing.